Aktia Bank Plc
Correction: Change in the number of own shares held by Aktia Bank Plc
Aktia Bank Plc
Stock Exchange Release
15 January 2021 at 10.00 a.m.
Correction: Change in the number of own shares held by Aktia Bank Plc
This release replaces the stock exchange release published by Aktia Bank Plc on 4 January 2021 at 3.00 p.m., which incorrectly stated that the number of own shares held by the company was 83,893.
Aktia Bank Plc has on 4 January 2021, supported by a decision taken by the company's Board of Directors, divested 29,595 own shares held by the company for payment of deferred instalments for the earning periods 2016–2017, 2017–2018, 2018–2019 and other incentive programmes to a total of 21 persons.
Following the divestment and the return of shares the company holds 83,777 own shares.
Aktia Bank Plc
Further information:
Outi Henriksson, CFO, tel. +358 10 247 6236
Distribution:
Nasdaq Helsinki Ltd
Mass media
www.aktia.com
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Norsk Hydro5.3.2021 07:32:40 CET | Press release
Norsk Hydro: Invitation to Investor presentation - Hydro agrees to sell Rolling business area to KPS Capital Partners
Aktieselskabet Schouw & Co.5.3.2021 07:32:10 CET | Press release
Annual Report 2020: The conglomerate shows its strength
Aktieselskabet Schouw & Co.5.3.2021 07:32:00 CET | Pressemeddelelse
Årsrapport 2020: Konglomeratet viser sin styrke
Norsk Hydro5.3.2021 07:31:49 CET | Press release
Norsk Hydro: Hydro agrees to sell Rolling business area to KPS Capital Partners for EUR 1,380 million
Heijmans NV5.3.2021 07:31:39 CET | Press release
Heijmans and AM join forces in Feyenoord City Rotterdam
Hyloris Pharmaceuticals5.3.2021 07:02:18 CET | Press release
Hyloris’ Partner AFT Pharmaceuticals Signs Licensing Agreement with Aguettant for Maxigesic® IV in Eight European Markets
F. Hoffmann-La Roche Ltd5.3.2021 07:02:08 CET | Press release
Roche’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom